GEN Exclusives

More »

GEN News Highlights

More »
Apr 19, 2011

Ambry Genetics to Provide Entire Roche NimbleGen Array Portfolio

  • Ambry Genetics has officially become a Certified Service Provider (CSP) for NimbleGen comparative genomic hybridization (CGH), chromatin immunoprecipiation-on-chip (ChIP-chip), DNA methylation, and gene expression. The firm, Roche NimbleGen’s first CSP in the U.S., is now certified on all Roche NimbleGen applications, the first CSP to attain this status.

    A CAP-accredited, CLIA-certified commercial clinical laboratory, Ambry Genetics will process customer samples for copy number variation, DNA methylation analysis, gene-expression analysis, and DNA-protein interactions and chromatin structure. The company will use the complete NimbleGen Dual- and Single-Color microarray workflow, which includes the high-resolution MS 200 Microarray Scanner.

    Ambry was initiated as a Roche NimbleGen CSP in the U.S. during September 2010. The company became a supplier of NimbleGen's SeqCap EZ Exome sequence-capture technology, giving it the ability to offer target-enrichment services coupled with next-generation sequencing services for genetic research.

    Earlier this month Ambry Genetics became the first authorized CSP in Ion Torrent's new service provider program. Ion Torrent develops a sequencing system using semiconductor technology.

     


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?